(NTR) Nutrien - Overview
Exchange: NYSE •
Country: Canada •
Currency: USD •
Type: Common Stock •
ISIN: CA67077M1086
Stock:
Total Rating 63
Risk 77
Buy Signal 0.37
| Risk 5d forecast | |
|---|---|
| Volatility | 30.4% |
| Relative Tail Risk | -3.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.35 |
| Alpha | 37.48 |
| Character TTM | |
|---|---|
| Beta | 0.402 |
| Beta Downside | 0.981 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.19% |
| CAGR/Max DD | 0.01 |
EPS (Earnings per Share)
Revenue
Description: NTR Nutrien
Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Nutrien Ag Solutions, Potash, Nitrogen, and Phosphate. The Nutrien Ag Solutions segment distributes crop nutrients, crop protection products, seeds, and merchandise products; product application, soil and leaf testing, crop scouting, precision agriculture, water, and brokerage agency services; and financing solutions. The Potash segment provides granular and standard potash products. The Nitrogen segment offers ammonia, urea, environmentally smart nitrogen, nitrogen solutions, nitrates, and sulfates. The Phosphate segment provides solid fertilizer, liquid fertilizer, and industrial and feed products. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 2.27b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.06 > 1.0 |
| NWC/Revenue: 13.76% < 20% (prev 6.73%; Δ 7.03% < -1%) |
| CFO/TA 0.08 > 3% & CFO 4.05b > Net Income 2.27b |
| Net Debt (12.23b) to EBITDA (5.98b): 2.05 < 3 |
| Current Ratio: 1.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (483.2m) vs 12m ago -1.97% < -2% |
| Gross Margin: 31.06% > 18% (prev 0.29%; Δ 3077 % > 0.5%) |
| Asset Turnover: 51.71% > 50% (prev 50.10%; Δ 1.61% > 0%) |
| Interest Coverage Ratio: 5.24 > 6 (EBITDA TTM 5.98b / Interest Expense TTM 687.9m) |
Altman Z'' 2.67
| A: 0.07 (Total Current Assets 14.72b - Total Current Liabilities 11.02b) / Total Assets 52.21b |
| B: 0.23 (Retained Earnings 12.05b / Total Assets 52.21b) |
| C: 0.07 (EBIT TTM 3.61b / Avg Total Assets 52.02b) |
| D: 0.94 (Book Value of Equity 25.22b / Total Liabilities 26.89b) |
| Altman-Z'' Score: 2.67 = A |
Beneish M -2.98
| DSRI: 1.18 (Receivables 5.66b/4.63b, Revenue 26.90b/25.97b) |
| GMI: 0.93 (GM 31.06% / 28.99%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.30) |
| SGI: 1.04 (Revenue 26.90b / 25.97b) |
| TATA: -0.03 (NI 2.27b - CFO 4.05b) / TA 52.21b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of NTR shares?
As of March 01, 2026, the stock is trading at USD 75.07 with a total of 3,408,993 shares traded.
Over the past week, the price has changed by +5.44%, over one month by +6.75%, over three months by +30.19% and over the past year by +48.51%.
Over the past week, the price has changed by +5.44%, over one month by +6.75%, over three months by +30.19% and over the past year by +48.51%.
Is NTR a buy, sell or hold?
Nutrien has received a consensus analysts rating of 3.88.
Therefore, it is recommended to buy NTR.
- StrongBuy: 10
- Buy: 5
- Hold: 8
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the NTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 72.9 | -3% |
| Analysts Target Price | 72.9 | -3% |
NTR Fundamental Data Overview February 24, 2026
P/E Trailing = 19.1914
P/E Forward = 11.8483
P/S = 1.3364
P/B = 1.1571
P/EG = 0.6571
Revenue TTM = 26.90b USD
EBIT TTM = 3.61b USD
EBITDA TTM = 5.98b USD
Long Term Debt = 9.85b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.73b USD (from shortTermDebt, last quarter)
Debt = 12.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.23b USD (from netDebt column, last quarter)
Enterprise Value = 46.91b USD (34.68b + Debt 12.93b - CCE 699.7m)
Interest Coverage Ratio = 5.24 (Ebit TTM 3.61b / Interest Expense TTM 687.9m)
EV/FCF = 23.66x (Enterprise Value 46.91b / FCF TTM 1.98b)
FCF Yield = 4.23% (FCF TTM 1.98b / Enterprise Value 46.91b)
FCF Margin = 7.37% (FCF TTM 1.98b / Revenue TTM 26.90b)
Net Margin = 8.44% (Net Income TTM 2.27b / Revenue TTM 26.90b)
Gross Margin = 31.06% ((Revenue TTM 26.90b - Cost of Revenue TTM 18.55b) / Revenue TTM)
Gross Margin QoQ = 35.36% (prev 32.70%)
Tobins Q-Ratio = 0.90 (Enterprise Value 46.91b / Total Assets 52.21b)
Interest Expense / Debt = 1.44% (Interest Expense 185.8m / Debt 12.93b)
Taxrate = 21.41% (160.4m / 749.3m)
NOPAT = 2.83b (EBIT 3.61b * (1 - 21.41%))
Current Ratio = 1.34 (Total Current Assets 14.72b / Total Current Liabilities 11.02b)
Debt / Equity = 0.51 (Debt 12.93b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 2.05 (Net Debt 12.23b / EBITDA 5.98b)
Debt / FCF = 6.17 (Net Debt 12.23b / FCF TTM 1.98b)
Total Stockholder Equity = 24.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.36% (Net Income 2.27b / Total Assets 52.21b)
RoE = 9.13% (Net Income TTM 2.27b / Total Stockholder Equity 24.88b)
RoCE = 10.38% (EBIT 3.61b / Capital Employed (Equity 24.88b + L.T.Debt 9.85b))
RoIC = 7.54% (NOPAT 2.83b / Invested Capital 37.58b)
WACC = 5.70% (E(34.68b)/V(47.61b) * Re(7.40%) + D(12.93b)/V(47.61b) * Rd(1.44%) * (1-Tc(0.21)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.18%
[DCF] Terminal Value 81.72% ; FCFF base≈1.76b ; Y1≈1.22b ; Y5≈622.3m
[DCF] Fair Price = 15.26 (EV 19.61b - Net Debt 12.23b = Equity 7.38b / Shares 483.3m; r=5.90% [WACC]; 5y FCF grow -35.86% → 2.90% )
EPS Correlation: -50.71 | EPS CAGR: -26.99% | SUE: -0.55 | # QB: 0
Revenue Correlation: -44.53 | Revenue CAGR: -8.79% | SUE: 2.37 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.51 | Chg7d=+0.038 | Chg30d=+0.034 | Revisions Net=-1 | Analysts=12
EPS current Year (2026-12-31): EPS=4.79 | Chg7d=+0.049 | Chg30d=+0.045 | Revisions Net=+4 | Growth EPS=+5.1% | Growth Revenue=+2.2%
EPS next Year (2027-12-31): EPS=4.67 | Chg7d=+0.079 | Chg30d=+0.099 | Revisions Net=+3 | Growth EPS=-2.5% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.7% (Discount Rate 7.9% - Earnings Yield 5.2%)
[Growth] Growth Spread = +5.7% (Analyst 8.4% - Implied 2.7%)
P/E Forward = 11.8483
P/S = 1.3364
P/B = 1.1571
P/EG = 0.6571
Revenue TTM = 26.90b USD
EBIT TTM = 3.61b USD
EBITDA TTM = 5.98b USD
Long Term Debt = 9.85b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.73b USD (from shortTermDebt, last quarter)
Debt = 12.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.23b USD (from netDebt column, last quarter)
Enterprise Value = 46.91b USD (34.68b + Debt 12.93b - CCE 699.7m)
Interest Coverage Ratio = 5.24 (Ebit TTM 3.61b / Interest Expense TTM 687.9m)
EV/FCF = 23.66x (Enterprise Value 46.91b / FCF TTM 1.98b)
FCF Yield = 4.23% (FCF TTM 1.98b / Enterprise Value 46.91b)
FCF Margin = 7.37% (FCF TTM 1.98b / Revenue TTM 26.90b)
Net Margin = 8.44% (Net Income TTM 2.27b / Revenue TTM 26.90b)
Gross Margin = 31.06% ((Revenue TTM 26.90b - Cost of Revenue TTM 18.55b) / Revenue TTM)
Gross Margin QoQ = 35.36% (prev 32.70%)
Tobins Q-Ratio = 0.90 (Enterprise Value 46.91b / Total Assets 52.21b)
Interest Expense / Debt = 1.44% (Interest Expense 185.8m / Debt 12.93b)
Taxrate = 21.41% (160.4m / 749.3m)
NOPAT = 2.83b (EBIT 3.61b * (1 - 21.41%))
Current Ratio = 1.34 (Total Current Assets 14.72b / Total Current Liabilities 11.02b)
Debt / Equity = 0.51 (Debt 12.93b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 2.05 (Net Debt 12.23b / EBITDA 5.98b)
Debt / FCF = 6.17 (Net Debt 12.23b / FCF TTM 1.98b)
Total Stockholder Equity = 24.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.36% (Net Income 2.27b / Total Assets 52.21b)
RoE = 9.13% (Net Income TTM 2.27b / Total Stockholder Equity 24.88b)
RoCE = 10.38% (EBIT 3.61b / Capital Employed (Equity 24.88b + L.T.Debt 9.85b))
RoIC = 7.54% (NOPAT 2.83b / Invested Capital 37.58b)
WACC = 5.70% (E(34.68b)/V(47.61b) * Re(7.40%) + D(12.93b)/V(47.61b) * Rd(1.44%) * (1-Tc(0.21)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.18%
[DCF] Terminal Value 81.72% ; FCFF base≈1.76b ; Y1≈1.22b ; Y5≈622.3m
[DCF] Fair Price = 15.26 (EV 19.61b - Net Debt 12.23b = Equity 7.38b / Shares 483.3m; r=5.90% [WACC]; 5y FCF grow -35.86% → 2.90% )
EPS Correlation: -50.71 | EPS CAGR: -26.99% | SUE: -0.55 | # QB: 0
Revenue Correlation: -44.53 | Revenue CAGR: -8.79% | SUE: 2.37 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.51 | Chg7d=+0.038 | Chg30d=+0.034 | Revisions Net=-1 | Analysts=12
EPS current Year (2026-12-31): EPS=4.79 | Chg7d=+0.049 | Chg30d=+0.045 | Revisions Net=+4 | Growth EPS=+5.1% | Growth Revenue=+2.2%
EPS next Year (2027-12-31): EPS=4.67 | Chg7d=+0.079 | Chg30d=+0.099 | Revisions Net=+3 | Growth EPS=-2.5% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.7% (Discount Rate 7.9% - Earnings Yield 5.2%)
[Growth] Growth Spread = +5.7% (Analyst 8.4% - Implied 2.7%)